Sector News

GSK re-hires China government relations exec linked to whistleblower probe

August 3, 2015
Life sciences
(Reuters) – Britain’s GlaxoSmithKline PLC said on Monday it had re-hired Vivian Shi, a former Chinese government affairs executive at the firm who was the focus of an internal probe into information leaks alleging bribery at the company’s China unit.
 
GSK was fined $489 million last year after a Chinese police investigation concluded the firm had paid doctors to prescribe its drugs, underlining steep compliance risks for firms in the world’s second largest economy.
 
Shi was named in the internal investigation carried out on behalf of GSK China into a series of emails alleging bribery by the British firm, and which were sent to Chinese government agencies and senior GSK staff, according to a June 2013 summary of the investigation seen by Reuters.
 
The investigation did not prove Shi, who had left her job in 2012 and before the bribery investigation came to light, was behind the emails.
 
GSK declined to comment on specific questions about the case.
 
“We can confirm we have rehired Vivian,” the firm said in an emailed statement. “We are not going to comment further on an individual employee.”
 
“Vivian herself is not available for comment,” it added. Shi could not be reached separately for comment.
 
China is the world’s second largest drug market by sales, where spending is set to hit as much as $185 billion by 2018, according to estimates by IMS Health.
 
The June 2013 report into the information leaks was compiled by ChinaWhys, a risk management consultancy run by British investigator Peter Humphrey and his American wife Yu Yingzeng, who were arrested in China for illegally obtaining private records of Chinese citizens and selling the information to clients, which included GSK.
 
The couple were released from prison and deported in June.
 
GSK apologised last year after it was found guilty of bribing doctors, saying it had “learned from its mistakes” and would “work hard to regain the trust of the Chinese people”. (Reporting by Adam Jourdan; Editing by Miral Fahmy)

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach